Molecule intelOpportunity: Moderate0

Clonazepam

26 brands · 24 companies · product forms

1 DRAP alert

Opportunity snapshot

Launch attractiveness
40
Market saturation
61
Price room
80
Regulatory risk
50
26
brands
24
companies
Rs 85
median price
6
price points
4.2x
price spread
90
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 4%

Price room

Across observed sources and strengths
CheapestRs 42.4
MedianRs 85
Most expensiveRs 178
Spread4.2×
Sources: DVAGO, Servaid

max/min price ratio 4.20x across 6 trusted points (Rs 42.4-178.0). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 10 live products for Clonazepam — each links to its own medicine page.

Regulatory alerts

Recall exposurelatest 2025-06-19
Recall Alert: Recall of Substandard “Tovir 0.5mg Tablet” Batch No. 55, Manufactured by M/s

Why this score

Launch attractiveness

40% supply-gap(20) + 25% price-variation(80) + 20% low-competition(39) + 15% supply-disruption(40), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

24 canonical companies and 26 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 4.20x across 6 trusted points (Rs 42.4-178.0). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2025-06-19 incl. recall/safety.

Confidence

Reduced by: no ATC code.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.